Browse the evidence

GLP-1 receptor agonists (semaglutide 2.4 mg) and dual GIP/GLP-1 agonists (tirzepatide) reduce major adverse cardiovascular events (MACE) in obese patients without diabetes, independent of weight loss alone.

If you are obese and have existing heart disease, ask your doctor about GLP-1 agonists like semaglutide. They significantly lower your risk of heart attack and stroke, offering protection beyond just weight loss.

GLP-1 and GIP/GLP-1 agonists improve heart failure with preserved ejection fraction (HFpEF) symptoms and functional capacity in obese patients, independent of diabetes status.

If you have obesity and heart failure with preserved ejection fraction, discuss GLP-1 agonists with your cardiologist. They can significantly improve your heart failure symptoms, exercise capacity, and quality of life.

GLP-1 and GIP receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease, independent of weight loss magnitude.

For patients with type 2 diabetes and existing heart disease, GLP-1 therapies like liraglutide and semaglutide significantly reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death). This benefit exists alongside weight loss and may be partly due to direct protective effects on the heart and blood vessels. These drugs are now a standard part of care for high-risk diabetic patients.

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce cardiovascular death, heart failure hospitalizations, and renal composite outcomes in patients with type 2 diabetes and chronic kidney disease, regardless of baseline glycemic control.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors like empagliflozin or dapagliflozin. These medications are proven to significantly lower your risk of heart failure, kidney failure, and death, offering protection beyond just blood sugar control.

GLP-1 receptor agonists (liraglutide, semaglutide) reduce major adverse cardiovascular events (MACE) and nephropathy progression in high-risk patients with Type 2 Diabetes.

For those with Type 2 Diabetes and high heart risk, GLP-1 agonists like liraglutide or semaglutide offer strong protection against heart attacks and strokes, as well as kidney damage. Discuss these options with your doctor, especially if you are overweight.

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about SGLT-2 inhibitors (like empagliflozin or dapagliflozin). These drugs protect your heart and kidneys beyond just lowering blood sugar, significantly reducing the risk of heart failure hospitalization and death. Be aware of potential side effects like infections, but discuss how the heart benefits may outweigh these risks for your specific health profile.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce Major Adverse Cardiovascular Events (MACE) and all-cause mortality in patients with Type 2 Diabetes and established CVD, primarily through weight loss, blood pressure reduction, and anti-inflammatory effects.

If you have Type 2 Diabetes and heart disease, GLP-1 agonists (like semaglutide or liraglutide) are highly effective at reducing the risk of heart attacks, strokes, and death. They work by mimicking a gut hormone to lower blood sugar, promote weight loss, and reduce blood pressure. While they require injections and may cause temporary stomach issues, the heart protection benefits are substantial and well-documented.

Obesity increases the risk of various cancers (e.g., breast, colorectal, liver) through mechanisms involving chronic inflammation, oxidative stress, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin).

Obesity increases your risk for several types of cancer through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Obesity contributes to cardiovascular disease (CVD) through mechanisms including adipose tissue dysfunction, ectopic fat deposition, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin), leading to hypertension, atherosclerosis, and heart failure.

Obesity increases your risk for heart disease and stroke through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Discontinuation of semaglutide or tirzepatide leads to significant weight regain, indicating that these therapies require long-term use to maintain metabolic benefits.

If you stop taking semaglutide or tirzepatide, you will likely regain most of the weight you lost. These drugs treat obesity and diabetes as chronic conditions, meaning they are meant to be taken long-term to maintain the health benefits. Stopping them reverses the progress made.

Men experience greater magnitude of weight loss and cardiometabolic improvement (insulin sensitivity, lipids) from low-calorie diets than women, but women maintain these benefits better during weight maintenance due to lower metabolic rebound.

If you are a woman, expect your initial weight loss on a strict low-calorie diet to be slower than a man's, but recognize that your body may be better at keeping your blood fats and insulin sensitivity stable once you stop dieting. Focus on the long-term maintenance of health markers rather than just the scale number during the first 8 weeks.

Semaglutide treatment is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) compared to placebo, though these are mostly mild to moderate.

Be prepared for gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but usually mild and temporary. Titration helps manage them.

Pharmacological treatment of hypertension significantly reduces major cardiovascular events, including heart failure, stroke, and mortality, regardless of baseline blood pressure levels.

If diagnosed with hypertension, adhere to prescribed pharmacological treatment. Fixed-dose combinations are often recommended to improve adherence and minimize side effects. The reduction in cardiovascular risk is substantial and consistent across different baseline risks.

Chronic low-grade inflammation in adipose tissue, driven by M1 macrophage infiltration and pro-inflammatory cytokine secretion (TNF-α, IL-1β, IL-6), directly causes insulin resistance and contributes to the pathogenesis of Type 2 Diabetes.

For obese individuals, reducing body fat is critical not just for weight loss, but to reduce the chronic inflammation in fat tissue that blocks insulin. This inflammation directly impairs how your body uses glucose, increasing the risk of Type 2 Diabetes. Weight loss interventions that reduce this inflammation can improve insulin sensitivity.

Obesity increases the risk of postmenopausal estrogen receptor-positive (ER+) breast cancer and is associated with worse disease outcomes and higher mortality across all breast cancer subtypes.

For postmenopausal women, maintaining a healthy weight is critical to reducing the risk of developing estrogen-receptor-positive breast cancer and improving survival rates if diagnosed. This is achieved through lifestyle interventions that lower circulating estrogens and inflammatory markers.

Muscle hypertrophy is driven by the PI3K-AKT-mTOR pathway, where IGF-1 and insulin signaling promote protein synthesis and inhibit degradation, while myostatin/activin signaling via Smad2/3 inhibits growth.

To build muscle, your body relies on specific hormonal signals like IGF-1 and insulin to activate the mTOR pathway, which drives protein synthesis and blocks breakdown. Conversely, myostatin acts as a brake on growth. Understanding this balance explains why resistance training (which stimulates these pathways) is effective, while conditions that elevate myostatin or impair insulin signaling can hinder growth.

Elevated levels of triglyceride-rich lipoproteins (TRL) and their remnants are causally associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, ischemic stroke, and aortic valve stenosis, independent of LDL cholesterol levels.

High triglycerides are not just a number; they represent particles that directly contribute to heart disease. If your triglycerides are consistently above 1.2 mmol/L (100 mg/dL), you have elevated cardiovascular risk, even if your LDL is normal. Managing this involves dietary changes to reduce carbohydrate and alcohol intake, and potentially medication if lifestyle changes are insufficient, especially if you have diabetes or existing heart disease.

Apolipoprotein CIII (apoCIII) acts as a key inhibitor of lipoprotein lipase (LpL), and its reduction leads to more efficient clearance of triglycerides from the blood, thereby lowering plasma triglyceride levels and potentially reducing cardiovascular risk.

High levels of apoCIII slow down the breakdown of fat particles in your blood. This is often driven by insulin resistance. Managing insulin sensitivity through diet and exercise can naturally lower apoCIII levels, helping your body clear triglycerides more efficiently.

Type 2 diabetes mellitus (T2DM) and insulin resistance are significant independent risk factors for the progression of NAFLD to NASH, fibrosis, and cirrhosis, and are associated with increased mortality.

If you have NAFLD and Type 2 Diabetes, managing your blood sugar and insulin resistance is critical to preventing liver damage. T2DM is an independent risk factor for progression to cirrhosis and liver-related mortality.

GLP-1 receptor agonists (GLP-1RAs) effectively treat type 2 diabetes and obesity by mimicking endogenous GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite via central nervous system signaling.

GLP-1 medications are highly effective for managing type 2 diabetes and obesity. They work by mimicking a natural hormone to boost insulin when needed, lower blood sugar, slow digestion, and reduce hunger. While they often require injections, many are now available as once-weekly shots or even pills. Side effects like nausea are common at first but usually fade. They are not for type 1 diabetes. Always combine with diet and exercise.

Obesity (excess body fatness) is a convincing risk factor for at least 13 different cancer sites, including endometrial, postmenopausal breast, colorectal, esophageal, renal, meningioma, pancreatic, gastric cardia, liver, multiple myeloma, ovarian, gallbladder, and thyroid cancers.

Maintain a healthy body weight to reduce cancer risk. Focus on sustainable lifestyle changes like balanced nutrition and regular activity rather than rapid weight loss, as avoiding weight gain is a viable preventive measure.

Subcutaneous white adipose tissue (WAT) expansion is metabolically protective, whereas preferential visceral WAT expansion is associated with increased risk for insulin resistance and metabolic syndrome.

Monitor your waist circumference as a proxy for visceral fat. A high waist-to-hip ratio indicates visceral fat accumulation, which is a stronger risk factor for diabetes and heart disease than overall BMI. Prioritize strategies that favor subcutaneous fat storage or prevent visceral accumulation, such as regular aerobic exercise and stress management.

Insulin resistance in skeletal muscle and adipose tissue, characterized by impaired GLUT4 translocation, is a primary driver of whole-body hyperglycemia and type 2 diabetes.

Maintaining insulin sensitivity through regular physical activity (which stimulates GLUT4 translocation independently of insulin) and managing body fat levels are critical for preventing the transition from insulin resistance to type 2 diabetes.

Skeletal muscle is responsible for over 80% of postprandial glucose uptake, making it the primary driver of whole-body insulin resistance and glucose homeostasis.

Your skeletal muscle is the main engine for processing sugar from your food. When muscle function declines (due to aging or inactivity), your body struggles to manage blood sugar, leading to insulin resistance. Prioritizing muscle maintenance through activity is a fundamental strategy for metabolic health.